Loading patent…
AssigneeLunella Biotech, Inc.
InventorsMichael P. LISANTI, Federica SOTGIA
Estimating the term…
Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial targeting signaling in living cells. TPP-related compounds may be utilized to target mitochondria in cancer stem cells (CSC5), and may be used for treating and/or preventing tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance, as well as for anticancer therapies. Various TPP-related compounds validated for oxygen consumption inhibition (OCR), were non-toxic, and had little or no effect on ATP production in normal human fibroblasts. Yet these compounds selectively target adherent “bulk” cancer cells. These compounds also inhibit the propagation of CSCs in suspension. TPP-related compounds provide a novel chemical strategy for effectively targeting both i) “bulk” cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells, among other useful therapies.
1-27. (canceled)
A method for preventing at least one of tumor recurrence and tumor metastasis, the method comprising administering to a patient in need thereof a pharmaceutically effective amount of a TPP-derivative compound selected from the group consisting of 2-butene-1,4-bis-TPP;
A method for treating cancer, the method comprising administering to a patient in need thereof a pharmaceutically effective amount of a TPP-derivative compound selected from the group consisting of 2-butene-1,4-bis-TPP;
An anti-cancer pharmaceutical composition comprising a TPP-derivative compound selected from the group consisting of 2-butene-1,4-bis-TPP;
Dependencies are inferred from the claim text.